title: Glargine and cancer: can we now suggest closure?
authors.affiliation: Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK. owensdr@cardiff.ac.uk
authors.forename: David R
authors.initials: DR
authors.lastname: Owens
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000097:blood*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics*; D008297:Male
chemical_list: D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine